Edition:
United States

Qiagen NV (QGEN.OQ)

QGEN.OQ on NASDAQ Stock Exchange Global Select Market

32.92USD
11:37am EDT
Change (% chg)

$0.31 (+0.95%)
Prev Close
$32.61
Open
$32.88
Day's High
$32.93
Day's Low
$32.77
Volume
49,430
Avg. Vol
234,183
52-wk High
$32.93
52-wk Low
$20.71

Latest Key Developments (Source: Significant Developments)

Qiagen reports Q1 adjusted earnings per share $0.22
Tuesday, 2 May 2017 04:05pm EDT 

May 2 (Reuters) - Qiagen NV :Qiagen nv - reaffirms full-year 2017 outlook for 6-7% cer sales growth and adjusted eps target before restructuring costs of $1.25-1.27 cer.Fy2017 earnings per share view $1.23, revenue view $1.41 billion -- Thomson Reuters I/B/E/S.Qiagen NV qtrly earnings per share $0.08.Qiagen reports results for first quarter 2017.Q1 adjusted earnings per share $0.22.Q1 revenue $307.7 million versus i/b/e/s view $306.9 million.Q1 earnings per share view $0.21 -- Thomson Reuters I/B/E/S.Qiagen NV - for the second quarter of 2017, adjusted net sales are expected to rise approximately 5-6% cer.Qiagen NV - for the second quarter of 2017, adjusted diluted eps are expected to be approximately $0.28-0.29 cer on an underlying basis.  Full Article

Qiagen partners with Maccura to localize GeneReader NGS System in China
Tuesday, 2 May 2017 02:00am EDT 

May 2 (Reuters) - Qiagen Nv :Qiagen partners with Maccura to localize and commercialize GeneReader NGS system in China.Qiagen NV-JV, named MAQGEN plans to accelerate local adaptations, development and commercialization of GeneReader NGS System in China.  Full Article

Qiagen expands liquid biopsy pipeline with AR-V7 test in prostate cancer
Friday, 31 Mar 2017 04:05pm EDT 

Qiagen Nv : Qiagen expands liquid biopsy pipeline with AR-V7 test in prostate cancer .Qiagen NV - Qiagen has acquired an exclusive worldwide license from Johns Hopkins University.  Full Article

BRIEF-Qiagen Q4 adjusted eps $0.15
Wednesday, 1 Feb 2017 04:05pm EST 

Corrects 6th and 7th bullet to say company reported, not expects 2016 adj. EPS of $0.87 and EPS of $0.34.Qiagen NV : Qiagen NV qtrly earnings per share $0.04 . Qiagen NV qtrly adjusted EPS $0.15 . Qiagen reaffirms full-year 2017 outlook for 6-7 pct CER sales growth . Reports results for fourth quarter and full-year 2016 . Q4 sales $366.5 million versus I/B/E/S view $370.7 million . Reports 2016 adjusted EPS $0.87 . Reports 2016 EPS $0.34 .Reaffirms full-year 2017 outlook for adjusted EPS target before restructuring costs of $1.25-1.27 CER.  Full Article

Qiagen NV Q4 SHR $0.04
Wednesday, 1 Feb 2017 04:05pm EST 

Qiagen NV : Reports 2016 adjusted EPS $0.87 . Reports 2016 EPS $0.34 . Qtrly Earnings Per Share $0.04 . Qtrly adjusted EPS $0.15 . Qiagen reaffirms full-year 2017 outlook for 6-7% CER sales growth . Qiagen reports results for fourth quarter and full-year 2016 . Q4 sales $366.5 million versus I/B/E/S view $370.7 million .Reaffirms full-year 2017 outlook for adjusted EPS target before restructuring costs of $1.25-1.27 cer.  Full Article

Singulex says entered into a strategic collaboration with Qiagen
Tuesday, 10 Jan 2017 09:00am EST 

Qiagen Nv : Singulex says entered into a strategic collaboration with Qiagen . Through collaboration, Qiagen will have access to Singulex's single molecule counting immunodiagnostic platform .Additionally, Qiagen will have access to Singulex's clia-licensed laboratory.  Full Article

Qiagen announces acquisition of OmicSoft Corporation
Monday, 9 Jan 2017 10:10am EST 

Qiagen NV : Qiagen enhances bioinformatics portfolio with acquisition of OmicSoft .Financial terms of the acquisition, which was completed in January 2017 using cash reserves, were not disclosed.  Full Article

Qiagen wants to expand with at least 2 emerging technologies per yr
Tuesday, 15 Nov 2016 10:08am EST 

Qiagen : Says 2020 goal to advance tb detection with qft-plus clinical benefits . Says 2017 to 2020 goal genereader ngs system >20% share of oncology benchtop sequencing . Says 2017 to 2020 goal to drive double-digit CER sales growth . Says 2020 target: >$300 million of quantiferon-tb sales . Says 2017 to 2020 goal to expand quantiferon to other latent diseases . Says 2017 to 2020 goal expand portfolio by at least 2 emerging technologies per year Further company coverage: [QGEN.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1270;)).  Full Article

Qiagen shareholders approve return of about $250 mln in cash via synthetic share repurchase
Wednesday, 26 Oct 2016 05:54am EDT 

Qiagen NV : Qiagen shareholders approve return of approximately $250 million in cash to shareholders via synthetic share repurchase .Qiagen NV - capital repayment forms part of a commitment announced in July 2016 to return $300 million to shareholders by end of 2017.  Full Article

Qiagen shareholders approve repayment of $250 million
Wednesday, 26 Oct 2016 05:47am EDT 

Qiagen NV : Shareholders overwhelmingly approved a proposal to return approx. $250 million in cash to shareholders through a synthetic share repurchase plan . Capital repayment forms part of a commitment announced in july 2016 to return $300 million to shareholders by end of 2017 .Transactions are expected to be completed in early january 2017.  Full Article

More From Around the Web

BRIEF-Qiagen reports Q1 adjusted earnings per share $0.22

* Qiagen nv - reaffirms full-year 2017 outlook for 6-7% cer sales growth and adjusted eps target before restructuring costs of $1.25-1.27 cer